Merck prepares for post-antibiotic era with Cubist purchase
Monday, December 8, 2014 - 13:00
in Mathematics & Economics
Merck will spend $8.4 billion US to buy Cubist Pharmaceuticals and move deeper into treating so-called "superbugs" that have drawn dire warnings from global health organizations.